Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03594435 · ClinicalTrials.gov registry record · Phase 2
Ibudilast for the Treatment of Alcohol Use Disorder
A Phase 2 study of Alcohol Use Disorder, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT03594435 is a Phase 2 study of Alcohol Use Disorder that has completed, run by University of California, Los Angeles. The registered enrollment target is 102 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03594435, a Phase 2 study of Alcohol Use Disorder, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a double-blind, placebo-controlled randomized clinical trial of Ibudilast (IBUD) (50mg twice a day) for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week medication treatment period and 5 in-person visits over 16 weeks.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG Ibudilast
Study Locations (1)
California
- UCLA Addictions Laboratory - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03594435
The ClinicalTrials.gov registry entry for NCT03594435 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (69% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03594435 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03594435 about?
NCT03594435 is a clinical study titled "Ibudilast for the Treatment of Alcohol Use Disorder". This study is a double-blind, placebo-controlled randomized clinical trial of Ibudilast (IBUD) (50mg twice a day) for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week medication treatment period and 5 in-person visits over 16 weeks.
What is the current status of trial NCT03594435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2018-10-01. Estimated completion is 2023-04-19.
What conditions does trial NCT03594435 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT03594435?
The interventions under investigation include: Placebo oral capsule (DRUG), Ibudilast (DRUG).
Who is sponsoring clinical trial NCT03594435?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03594435 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.